- What is psilocybin? Inside Trump’s push for psychedelic treatments
- Parkview Dental Partners continues Florida expansion
- What this ASC leader says is driving poor outcomes
- UnityPoint opens CRC clinic in Wisconsin
- Loma Linda University Health taps new CDIO
- ‘Hospitals are stepping up’: Direct contracting gains traction in Indiana
- ‘The margin quickly goes to zero’: Why cardiology ASC economics are so precarious
- 70% of public believe at least 1 false health claim: Survey
- Cleveland Clinic’s AI strategy: Partner if you can, build if you must
- 4 ASC acquisitions in 1 month
- OpenAI launches ChatGPT for Clinicians: 6 things to know
- Hospital C-suites retool for new payment era
- J&J to debut AI cardiac mapping tool
- HHS seeks to remake preventive services task force
- 10 hospitals, health systems seeking pharmacy leaders
- Keck Medicine expands AI precision medicine push
- Missouri hospital files for bankruptcy, pursues sale
- Gene Cure For Inherited Deafness Effective, Long Lasting, Clinical Trial Finds
- Most Americans Worried About Brain Health, But Few Know How To Protect It
- ER Study Finds Major Gaps in Measles Immunity
- With trial win, Novo Nordisk eyes adolescent diabetes approval for oral semaglutide
- IVF 'Add On' Procedure Doesn't Work, Evidence Review Concludes
- Website Helps Dementia Patients And Caregivers Bond, Reminisce
- New Treatment Improves Survival for Aggressive Breast Cancer
- More than 60% of Americans using AI tools for medical information: survey
- Evonik to pump €80M into Slovakia production facility, add 50 jobs
- OpenAI launches ChatGPT for Clinicians, a free AI tool for physicians, NPs and pharmacists
- Deerfield trots into pharma sales software space with CRM-enhancing tool
- Merck’s new AI commercial strategy ‘reimagining engagement with HCPs’
- ‘It buys patients time’: GLP-1s show early promise in addiction treatment
- North American Dental Group appoints vice president of education, development
- Maryland dental assistant sentenced for illegal opioid distribution
- Physician owner, practice to pay $415K for fraud allegations
- South Carolina bills looks to ban mail-order orthodontics
- What matters most in ASC design?
- Care New England rolls out Butler Behavioral Health brand
- Opening Remarks at the 32nd Annual International Institute for Securities Market Growth and Development
- What ASCs are getting wrong about the cardiology migration
- Grand Canyon University to add 6,000 to behavioral health pipeline
- AMA urges federal oversight of mental health chatbots
- Dental supplier lays off staff after large fire destroys business
- Recovery Unplugged expands virtual outpatient behavioral care to Pennsylvania
- 8 million Americans used psilocybin in past year: Study
- Heartland Dental to open Illinois office
- Northwell Health opens $20M multispecialty site
- Novant Health, Amae partner on Charlotte behavioral health expansion
- Conservative think tank Paragon Health calls its shots on hospital policy reform
- Cardiologist named CMO at MDVIP
- North Carolina proposes 47% dental Medicaid reimbursement increase
- Connecticut FQHC resumes dental services after yearlong pause
- 4 DSOs expanding in Florida
- Washington dental practice suffers data breach
- Autism care provider closes New York Medicaid panels after rate cuts
- Amazon One Medical launches GLP-1 program integrated with primary care
- HIE participation lags in behavioral health facilities: 4 notes
- CDC Report on COVID Vaccine Blocked From Publication
- Moderna Starts Large Bird Flu Study Despite Earlier HHS Funding Loss
- RFK Jr. continues congressional hearing appearances to talk White House budget plan
- RFK Jr. Won't Commit to CDC Nominee's Vaccine Decisions
- Pentagon Drops Flu Vaccine Requirement For U.S. Military
- AbbVie to establish NC production base with $1.4B investment, creating 730-plus jobs
- Zocdoc partners with Yelp to allow real-time scheduling
- CMS delays Part D GLP-1 model amid skepticism from insurers
- CMS delays Part D GLP-1 model amid skepticism from insurers
- Amneal seizes 'golden era' for biosims with $1.1B Kashiv buyout
- Samsung Biologics posts massive revenue growth as labor union rally sets strike in motion
- Bullying, Politics Harm Mental Health Of Gender-Diverse Teens
- Male Infertility Linked To Cancer Risk
- Video Game Training Sharpens ER Doctors’ Split-Second Decisions
- Hidden Belly Fat Linked to Bladder Control in Women
- Mind-Controlled Bionic Suit Lets Paralyzed Patients Feel Every Step
- Napping Linked To Higher Risk Of Death Among Seniors, Study Finds
- Merck goes with Google for AI push, striking enterprise partnership worth up to $1B
- Oak HC/FT backs Courier Health's $50M series B to build out AI for the biopharma patient experience
- Elevance Health seeing shift to bronze tier in ACA plans
- Novartis launches ‘Sjöut for Sjögren’s campaign, teams with Carrie Ann Inaba
- Community Health Systems attributes Q1 volumes stumble to consumers' macroeconomic fears, payers' prior auth denials
- Children’s Activity Cubes Recalled Over Choking Hazard Risk
- Merck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynso
- 'Don't be a wimp,' Mark Cuban tells lawmakers hesitant to break up PBMs
- Study Finds AI Chatbots Can Give Misleading Health Advice
- Former Surgeon General Backs CDC Nominee, But Questions Remain on Vaccines
- Cantaloupes Recalled in Four States Due to Salmonella Risk
- Keynote Remarks at The Economic Club of Washington
- Merger to create nation's largest suicide prevention nonprofit
- Oz previews new plan to push states toward revalidating Medicaid providers
- Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
- Covera Health, Medmo combine to create end-to-end diagnostic imaging platform
- The Oral GLP-1 Tracker: Following the launch trajectories of Lilly’s Foundayo, Novo’s Wegovy pill
- Service Dogs Perform Tasks Akin To Human Caregivers, Researchers Say
- A Third Of Young Adults Are Couch Potatoes, Their Parents Say
- Powerful Antibiotic Combo Not Necessary For Simple Sinus Infections, Study Shows
- Black Women Hit Hardest By Pandemic-Related Rise In Pregnancy-Related Deaths
- Smoking, Vaping Weed Increases Risk Of Asthma Attacks Among Young Adults, Study Finds
- Less-Dangerous Painkillers, Gabapentinoids, Still Have High Risk For Drug Interactions
- AstraZeneca eyes 5th Ultomiris indication after kidney disease trial win
- In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
- UnitedHealth Group spotlights AI investments as part of operational turnaround
- ECRI spins out healthcare supply chain division into Staritas, backed by PE firm Accel-KKR
- UCB partners with Myasthenia Gravis Foundation of America on meal program targeting nutrition deserts
- Replimune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection
- Statement on the Amendments to Form PF
- Update on the SEC’s Work Toward Treasury Clearing Implementation
- 'Hospitals adverse to transparency'—clashing industry groups spar on mulligan 340B rebate pilot
- Amperos Health secures $16M in series A funding, unveils AI-native denial management solution
- “PF” Stands for Please Fix: Statement on the Proposed Amendments to Form PF
- A look inside Highmark and Spring Health's mental well-being partnership
- CVS, Mass General Brigham primary care deal would increase annual care spending by $40M, report predicts
- Beyond Reporting: Realizing Continuous Safety Surveillance for Medical Devices
- Beyond Reporting: Realizing Continuous Safety Surveillance for Medical Devices
- Safeguarding Scientific Publishing from AI Hallucinations and Fabricated Citations
- Safeguarding Scientific Publishing from AI Hallucinations and Fabricated Citations
- Why UnitedHealth Group is betting big on doulas
- AIDS Relief Program Sees Drops in Testing and Diagnoses After Disruptions
- Baby Food Recalled After Rat Poison Discovered in Jar
- Report Finds Drug Prices Rising Despite Trump Pricing Deals
- Trump Backs Psychedelic Research
- Styker Adds IVL Technology to Peripheral Vascular Portfolio with Amplitude Acquisition
- Styker Adds IVL Technology to Peripheral Vascular Portfolio with Amplitude Acquisition
- Hippocratic AI rolls out 2 new tools aimed at expanding clinical access, improving nurse workflow
- In Connecticut, doctors now sue patients most over medical bills, surpassing hospitals
- Sanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna's mNexspike
- Physician burnout falls for third year in 2025 to 42%, AMA data shows
- Naloxone's OD-Reversing Powers Challenged By Today's Opioids, Tests Show
- Extra Antibiotic Doesn't Reduce Infection Risk During Surgery To Fix Complex Fractures, Trial Finds
- Clinical Trial Suggests Two Simple Ways To Fight Chemo-Related Brain Fog
- E-Cigarette Taxes Won't Necessarily Cause An Increase In Smoking, Study Says
- Dreams Affect Your Morning Mood In Surprising Ways, Study Finds
- Weed Blunts Brain Development In Teens
- Genentech shifts Hemlibra marketing focus to patient stories as competition approaches
- Neurogene hires new CCO as it eyes commercial future for its Rett gene therapy
- Biovac nets $108M finance package to build Africa’s first fully integrated vaccine plant
- Biogen bullish on America with Durham Bulls team up
- New Clues Explain Why Immunotherapy Fails in Pancreatic Cancer
- Does My Child Have a Language Disorder?
- New Weight Loss Research Questions Need for GLP-1 Drugs
- Trump Names CDC Director Pick
- The Healthccare Burnout Backlask (pt 4): Why Contract Negotiation Has Become a Core Strategic Skill for Healthcare Administrators
- The Healthccare Burnout Backlask (pt 4): Why Contract Negotiation Has Become a Core Strategic Skill for Healthcare Administrators
- Remarks at the Options Market Structure Roundtable
- Cattywampus: Statement on the CAT Concept Release
- Butterflies and Condors: Remarks at the Options Market Roundtable
- Statement at the Roundtable on Options
- Opening Remarks at the Options Market Structure Roundtable
- FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
- FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
- Freedom of Associations
- Interfacing with our Inner Demons: Comments on the Division of Trading and Markets' Statement on Certain User Interfaces
- Roche’s Enspryng cuts relapse risk by 68% in rare neuroinflammatory disease
- Staff Statement Regarding Broker-Dealer Registration of Certain User Interfaces Utilized to Prepare Transactions in Crypto Asset Securities
Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi all signed onto Trump's Most Favored Nation plan today; the plan outlined in his July 31st letter to Big Pharma CEOs. This brings 14 of the 17 targeted Big Pharma companies into accord with MFN. AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer have previously reached MFN agreements with the Administration. AbbVie is said to be close to an MFN deal with the Administration. The status of Johnson & Johnson and Regeneron have not been publicly disclosed.
The agreement also requires $ 150 billion in domestic pharmaceutical manufacturing, research and development investment commitments from the nine companies:
Trump, nine pharmaceutical companies strike deal to cut prices
By Michael Erman, Jarrett Renshaw and Patrick Wingrove - December 19, 2025Summary
- Drugmakers to cut prices on most drugs sold to the Medicaid program
- U.S. patients pay the most for prescription medicines
Dec 19 (Reuters) - U.S. President Donald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government's Medicaid program and for cash payers, in his latest bid to align U.S. costs with those in other wealthy nations.
Bristol Myers Squibb (BMY.N), Gilead Sciences (GILD.O), and Merck (MRK.N), and Roche's (ROG.S) U.S. unit Genentech have struck deals. Novartis (NOVN.S), Amgen (AMGN.O), Boehringer Ingelheim, Sanofi (SASY.PA), and GSK (GSK.L) have also signed on.
Under the deals, each drugmaker will cut prices on most drugs sold to the Medicaid program for low-income people, senior administration officials said, promising "massive savings" on widely used medicines without giving specific figures.
U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations, and Trump has been pressuring drugmakers to lower their prices to what patients pay elsewhere.
The details of each deal were not immediately available but officials said they included agreements to cut cash-pay direct-to-consumer prices of select drugs sold potentially through the TrumpRx.gov website, to launch drugs in the U.S. at prices equal to - not lower than - those in other wealthy nations and to increase manufacturing. In return, companies can receive a three-year exemption from any tariffs.
MERCK'S JANUVIA, JANUMET ON TRUMPRx
Merck said it will sell its diabetes drugs Januvia, Janumet and Janumet XR - set to face generic competition next year - directly to U.S. consumers at about 70% off list prices. If approved, its experimental cholesterol drug enlicitide will also be offered through direct-to-consumer channels.
Enlicitide is one of two Merck drugs expected to receive a speedy review under the FDA's new, fast-track pathway, Reuters previously reported.
In July, Trump sent letters to leaders of 17 major drugmakers, urging them to offer so-called most-favored-nation prices to Medicaid and ensure new medicines launch at prices no higher than those in other wealthy countries.
Five companies had previously struck deals with the administration to rein in prices - Pfizer, Eli Lilly (LLY.N), AstraZeneca (AZN.L), Novo Nordisk (NOVOb.CO), and EMD Serono, the U.S. division of Germany's Merck KGaA (MRCG.DE).
The remaining three that have not announced deals are Regeneron (REGN.O), Johnson & Johnson (JNJ.N), and AbbVie (ABBV.N). Investors initially feared sweeping U.S. price controls, but the details of recent deals have largely eased those concerns. Reuters previously reported that AbbVie was expected to announce a deal on Friday.
Drugmakers on Friday committed to “most-favored-nation” pricing on all new U.S. drug launches across commercial, government and cash-pay markets, including the U.S. Medicare program for those aged 65 and over, officials said.
A portion of revenues from each company's foreign sales will also be remitted to the U.S. to offset costs, officials said.
The companies pledged together to invest more than $150 billion in U.S. for R&D and manufacturing, according to officials, although it was unclear whether that included earlier commitments. Several also agreed to donate drug ingredients to the U.S. strategic reserve.
Merck said it chipped in $70 billion of that sum.Analysts have noted that Medicaid, which accounts for only around 10% of U.S. drug spending, already benefits from substantial price discounts, exceeding 80% in some cases.
Pfizer, which announced its 2026 financial outlook on Tuesday, said the Medicaid discounts would result in price and margin compression next year.
The White House Fact Sheet:
Fact Sheet: President Donald J. Trump Announces Largest Developments to Date in Bringing Most-Favored-Nation Pricing to American Patients
The White House
December 19, 2025LOWERING DRUG PRICES FOR AMERICAN PATIENTS: Today, President Donald J. Trump announced nine new agreements with major pharmaceutical companies to lower prescription drug prices for Americans in line with the lowest prices paid by other developed nations (known as the most-favored-nation, or MFN, price).
- The nine manufacturers include Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi.
- The agreements reduce prices on drugs that treat numerous costly and chronic conditions, including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, human immunodeficiency virus (HIV), and certain cancers, among others.
- The agreements will provide every State Medicaid program in the country access to MFN drug prices on products made by the nine companies, resulting in billions of dollars in savings and continuing President Trump’s historic efforts to strengthen the program for the most vulnerable.
- The agreements ensure foreign nations can no longer use price controls to free ride on American innovation by guaranteeing MFN prices on all new innovative medicines the nine companies bring to market.
- The agreements require the nine companies to repatriate increased foreign revenue on existing products that they realize as a result of the President’s strong America First U.S. trade policies for the benefit of American patients.
- The agreements require the nine companies to offer medicines at a deep discount off the list price when selling directly to American patients through TrumpRx.
DELIVERING LOWER COSTS: Patients will be able to see massive price reductions on numerous products when purchasing directly through TrumpRx as a result of today’s actions. Select examples include:
- Amgen will reduce the price of its cholesterol-lowering drug Repatha from $573 to $239 for patients purchasing directly through TrumpRx.
- Bristol Myers Squibb will reduce the price of its HIV medication, Reyataz, from $1,449 to $217 for patients purchasing directly through TrumpRx.
- Boehringer Ingelheim will reduce the price of its type two diabetes medication, Jentadeuto, from $525 to $55 for patients purchasing directly through TrumpRx.
- Genentech will reduce the price of its flu medication, Xofluza, from $168 to $50 for patients purchasing directly through TrumpRx.
- Gilead Sciences will reduce the price of its Hepatitis C medication, Epclusa, from $24,920 to $2,425 for patients purchasing directly through TrumpRx.
- GSK will reduce the prices of its inhaler portfolio. Prices for the popular asthma inhaler Advair Diskus 500/50 will fall from $265 to $89 for patients purchasing directly through TrumpRx.
- Merck will reduce the price of its diabetes medication, Januvia, from $330 to $100 for patients purchasing directly through TrumpRx.
- Novartis will reduce the price of its Multiple Sclerosis medication, Mayzent, from $9,987 to $1,137 for patients purchasing directly through TrumpRx.
- Sanofi will reduce the price of its prescription blood thinner, Plavix, from $756 to $16 for patients purchasing directly through TrumpRx and Sanofi will list its insulin products at TrumpRx at $35 per month’s supply.
BOLSTERING NATIONAL HEALTH SECURITY BY INVESTING IN AMERICA: The pharmaceutical manufacturers involved in today’s announcement are committing to invest at least $150 billion collectively in U.S. manufacturing in the near term. Additionally, as part of the agreements, several companies are donating active pharmaceutical ingredients for key products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to reduce reliance on foreign nations and ensure the United States has an adequate supply of such products in the event of an emergency.
- GSK will contribute 98.8kg of albuterol, the active ingredient in a common rescue inhaler for people with asthma.
- Bristol Myers Squibb will contribute tablets representing 6.5 tons of apixaban, the active ingredient in the drug Eliquis, a blood thinner taken by millions of American patients.
- Merck will contribute 3.5 tons of ertapenem, an antibacterial medication used to treat complex infections.
DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on promises to ensure American patients no longer pay high prices to subsidize low prices in the rest of the world, something the political establishment did not believe was possible.
- On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions to bring American drug prices in line with those paid by similar nations.
- On July 31, 2025, President Trump sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations.
- Since September 30, 2025, President Trump has announced 14 deals with major pharmaceutical manufacturers to bring prices in line with those paid in other developed nations, which will provide substantial price relief on numerous products taken by millions of Americans.
- On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom (U.K.) that will increase the net price of new prescription drugs by 25% in the U.K., helping ensure they pay their fair share for innovative medicines.
Johnson & Johnson disclosed their MFN agreement late yesterday evening. Regeneron and AbbVie are still outstanding::
https://thehill.com/policy/healthcare/5681535-johnson-johnson-trump-drug-prices/
Johnson & Johnson announces drug pricing deal with Trump administration
By Nathaniel Weixel - January 9, 2026Johnson & Johnson said late Thursday it will lower prices for certain prescription drugs and match the rates in other countries, becoming the latest pharmaceutical company to strike a deal with the Trump administration in exchange for tariff relief.
The New Jersey-based health conglomerate was one of the 17 companies President Trump called out last summer to lower drug prices as part of his administration’s “most favored nation” push.
Drugmakers have been eager to strike voluntary deals to avoid punitive actions such as tariffs that could cut deeply into their profits. The only companies who received letters that have yet to strike deals with the administration are AbbVie and Regeneron.
“I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives and ensuring that the United States continues to lead the world in healthcare innovation,” Joaquin Duato, chair and chief executive of Johnson & Johnson, said in a statement.
Under the agreement, J&J will offer specific drugs for sale directly to consumers at significant discounts through the Trump administration’s forthcoming TrumpRx website. It will also offer its drugs to the Medicaid program at comparable prices to other developed countries. The company did not say which drugs were part of the agreement.
J&J also did not specify how long its tariff reprieve will be, saying the specific terms remain confidential.
The agreement follows similar deals the administration has already made with pharma companies like Amgen, Bristol Myers Squibb, Gilead, GSK, Merck, Novartis, Genentech and Sanofi.
J&J also said it is planning two new U.S. manufacturing facilities as part of a previously announced $55 billion investment: a cell therapy manufacturing site in Pennsylvania and a drug product manufacturing facility in North Carolina.
The company said construction is progressing on a $2 billion biologics manufacturing facility in Wilson, N.C., which will create about 5,000 skilled jobs in the state.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.
Sponsors
J & DE Family Charitable Fund
Friends
of MHF
Kelly Grotendiek
Philip Harbach
Dale Johnson
Drs. Jeffrey and Joni Jones
Vickie Kahle
Tammy Kipen
Marlin & Kathy Klumpp
Melanie Kurdys
Ruth Nobel
Patrick Peterson
Stephanie Poortenga
Jeanne Smit
Ben and Hope Staal
John Tuinstra
Jacki VanHuis
Sandy Walker
Sign Up for MHF Insights to keep up on the latest in Michigan Health Policy
